These findings underscore that cerebral ischemia triggers two concurrent processes: MMP-2-mediated occludin degradation and claudin-5 redistribution, both leading to early disruption of the BBB, particularly relevant when employing thrombolysis during stroke treatment [17]. The gene discussed is MMP2; the disease is stroke disorder.